Key takeaways
- The exact phrase appears in FDA’s diagnostics rules; for drugs, the laboratory-research rule (21 CFR 312.160) allows shipping only with a specific label, due diligence on the recipient, records and recovery of unused material.
- FDA judges intended use from objective evidence: claims, advertising, statements and the circumstances of the sale (21 CFR 201.128).
- FDA’s 2026 warning letters treated RUO-labelled peptides as unapproved new drugs when the seller’s website showed human use, even where product text used research language.
- The MHRA and the TGA have both said research-use claims do not move a product outside medicines law.
01Where the phrase comes from
“Research use only” is not a legal category of peptide in US drug law. The real rules that sit behind the phrase are narrow, and they come with duties.
Diagnostics. The exact phrase appears in FDA’s rules for in vitro diagnostic products. A product “in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product” must be labelled: “For Research Use Only. Not for use in diagnostic procedures.” (21 CFR 809.10(c)(2)(i)). That rule is about test kits and reagents, not substances that go into a body.
Drugs for laboratory research. For drugs, the relevant rule is 21 CFR 312.160. It lets a person ship a drug “intended solely for tests in vitro or in animals used only for laboratory research purposes” if it is labelled: “CAUTION: Contains a new drug for investigational use only in laboratory research animals, or for tests in vitro. Not for use in humans.” The label is only the first duty:
The shipper “shall use due diligence to assure that the consignee is regularly engaged in conducting such tests” and that the drug “will actually be used” for them.
Name and address of the expert who receives it, and the date, quantity and batch of each shipment, kept for 2 years and open to FDA on request.
Unused supplies come back when the investigation ends, or are disposed of in a way that does not expose humans to risk.
FDA can end that authorisation if the drug “is used for purposes other than bona fide scientific investigation”. A label on its own meets none of these duties.
02Intended use: what FDA actually looks at
Whether a peptide is regulated as a drug depends on its intended use. FDA’s regulation defines this as “the objective intent of the persons legally responsible for the labeling of an article”. That intent “may be shown by such persons’ expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article”, including “labeling claims, advertising matter, or oral or written statements” (21 CFR 201.128).
In the 2026 warning letters below, FDA cited the sellers’ own product pages and what they sold alongside the products. A “not for human consumption” line was one fact among many, and it was outweighed.
03How the 2026 warning letters treated RUO labels
In 2026 FDA’s drug centre sent warning letters to online peptide sellers. Each of the three below concluded that the products were unapproved new drugs, and each addressed the label directly:
| FDA letter | Label wording FDA quoted | FDA’s conclusion |
|---|---|---|
| 721806, 31 Mar 2026 | “Research Use Only” and “not intended for human consumption, medical use, or veterinary use” | “evidence obtained from your website establishes that your products are intended to be drugs for human use” |
| 729447, 17 Jun 2026 | “RESEARCH USE ONLY” and “not for human consumption” | Evidence “from your product labeling, including your website” establishes the products are intended to be drugs for human use |
| 735127, 24 Aug 2026 | “research use only” and “not for human consumption” | Same conclusion; the products are unapproved new drugs |
Two further points from the August letter. It cites bacteriostatic water marketed “as a solvent for reconstituting your products” as “providing the means to prepare an injectable drug for human administration”. And the product descriptions FDA quoted as evidence of intended use were written in research language: compounds “studied for” an effect, or “considered in preclinical models”. Research vocabulary on a product page did not change the outcome.
HHS’s October 2026 compounding policy describes its own purpose in the same terms: to “discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients.” That policy covers licensed pharmacies, federal facilities and physicians only. See the HHS policy explained.
04The UK and Australia, in brief
United Kingdom. The MHRA’s head of borderlines told STV News in March 2026: “We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations.” More: peptides and UK law.
Australia. The TGA’s April 2026 safety advisory says that “research use only” disclaimers do not make supply lawful and, on their own, do not “change a product’s regulatory status”, “permit importation”, or “remove advertising or supply obligations”. More: peptides and Australian law.
Clinicians in the US. One state has addressed a related question. Mississippi’s medical, nursing and pharmacy boards said in August 2026 that “patient consent forms purporting to identify a product as ‘research-grade’ do not mitigate or eliminate a provider’s professional or legal liability.”
05What this page can’t tell you
Whether a specific sale is lawful depends on facts this page cannot see: the recipient, the jurisdiction, the product’s full presentation and how it is used. In every document above, the label was never decisive on its own. For a view on a specific situation, ask a lawyer qualified where you are.
For the market-by-market picture, start at are peptides legal?
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.